Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.

Tarcocimab的临床和非临床数据突出了糖尿病视网膜病变患者6个月的有效性和持续良好的安全性。

KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity and durability in treatment-naïve and treatment-experienced patients and next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101.

KSI-501临床和非临床数据突出了未接受治疗和有治疗经验的患者的多次递增剂量安全性，生物活性和耐久性，以及KSI-501的3期开发和KSI-101的1b期开发的下一步。

Novel small molecules and protein therapeutics highlight potential for targeted, high drug-antibody-ratio (DAR) conjugates built on Kodiak's ABC Platform.

新型小分子和蛋白质治疗剂突出了建立在Kodiak ABC平台上的靶向高药物抗体比（DAR）缀合物的潜力。

PALO ALTO, Calif., May 2, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington..

加利福尼亚州帕洛阿尔托，2024年5月2日/PRNewswire/-Kodiak Sciences Inc.（纳斯达克：KOD），一家致力于研究、开发和商业化治疗高患病率视网膜疾病的转化疗法的生物制药公司，今天宣布，将于5月5日至9日在华盛顿州西雅图举行的视觉与眼科研究协会（ARVO）2024年会上就其临床和研究管道计划进行九次科学演示。。

'We present clinical and non-clinical data on our ABC Platform medicines tarcocimab and KSI-501. We also begin to disclose the progress and potential for our duet and triplet drug platform. Conjugates of different active pharmaceutical intermediates (API) such as proteins, peptides, macrocycles, oligonucleotides, and small molecules, all with high drug antibody ratio (DAR) and tailored release, can be designed and manufactured.

“我们在ABC平台药物tarcocimab和KSI-501上提供临床和非临床数据。我们还开始披露我们的二重唱和三重唱药物平台的进展和潜力。可以设计和制造具有高药物抗体比（DAR）和定制释放的不同活性药物中间体（API）的缀合物，例如蛋白质，肽，大环化合物，寡核苷酸和小分子。

We wrap these within the 15 years of science and development experience with our ABC Platform and its thousands of patient years of clinical safety data and our commercial scale manufacturing facility Ursus,' said Dr. Victor Perlroth, Chief Executive Officer of Kodiak Sciences. 'With many companies focused on engineering a better biologic or a better small molecule, we are instead extending our ABC Platform to make copolymer conjugates that power a next generation of targeted, high-DAR, multi-specific and multi-modality therapeutic candidates with relevance for retinal and systemic diseases.'.

Kodiak Sciences首席执行官维克托·佩尔罗斯（Victor Perlroth）博士说，我们利用ABC平台及其数千年的临床安全数据和我们的商业规模制造设施Ursus，在15年的科学和开发经验中总结了这些数据随着许多公司专注于设计更好的生物制剂或更好的小分子，我们正在扩展我们的ABC平台，以制造共聚物缀合物，为下一代靶向，高DAR，多特异性和多模式治疗候选物提供动力，这些候选物与视网膜和全身疾病有关。”。

Presentations on tarcocimab tedromer (KSI-301):

关于tarcocimab tedromer（KSI-301）的介绍：

Title: Tarcocimab tedromer (KSI-301) 5mg: outcomes of the Phase 3 GLOW1 Study in patients with non-proliferative diabetic retinopathy.Session Title: Diabetic retinopathy ISession Date and Time: May 6, 2024; 8:30 – 10:15 AM PTPresentation Type: Poster SessionPoster Number: 221 – B0116

标题：Tarcocimab tedromer（KSI-301）5mg：非增殖性糖尿病视网膜病变患者3期GLOW1研究的结果。会议标题：糖尿病视网膜病变会议日期和时间：2024年5月6日；8： 上午30:00–10:15 PT演示类型：海报会议海报编号：221–B0116

Approximately eight million people in the U.S. live with diabetic retinopathy (DR), which is the leading cause of vision loss in the working-age population. The adoption of approved anti-VEGF therapies for DR patients is constrained by their high treatment burden. Kodiak's GLOW1 study with tarcocimab showed for the first time that a therapeutic agent dosed in all patients on an every 6-month interval can successfully treat and prevent disease worsening in DR patients.

美国大约有800万人患有糖尿病视网膜病变（DR），这是工作年龄人群视力丧失的主要原因。DR患者采用经批准的抗VEGF疗法受到其高治疗负担的限制。Kodiak使用tarcocimab进行的GLOW1研究首次表明，每6个月给所有患者服用一次治疗剂，可以成功治疗和预防DR患者的疾病恶化。

Tarcocimab offers the hope of an achievable prevention and treatment strategy in real-world clinical practice for DR patients at risk of vision loss. Currently, the Phase 3 GLOW2 study is enrolling patients with DR, with the goal to enable tarcocimab's marketing authorization application..

Tarcocimab为有视力丧失风险的DR患者提供了在现实世界临床实践中可实现的预防和治疗策略的希望。目前，第三阶段GLOW2研究正在招募DR患者，目标是启用tarcocimab的营销授权应用程序。。

Title: Metabolic control in patients with non-proliferative diabetic retinopathy (NPDR) treated with anti-VEGF active injections or sham injections. Prespecified results from the Phase 3 GLOW Study in patients treated with tarcocimab tedromer.Session Title: Diabetic retinopathy IISession Date and Time: May 7, 2024; 8:30 – 10:15 AM PTPresentation Type: Poster SessionPoster Number: 323 – B0508.

标题：用抗VEGF活性注射或假注射治疗的非增殖性糖尿病视网膜病变（NPDR）患者的代谢控制。tarcocimab tedromer治疗患者的3期GLOW研究的预先指定结果。会议标题：糖尿病视网膜病变II会议日期和时间：2024年5月7日；8： 上午30:00–10:15 PT演示类型：海报会话海报编号：323–B0508。

The prespecified analysis of the GLOW1 study demonstrated that both the tarcocimab treatment arm and sham arm had negligible change in systemic metabolic control as measured by HbA1c levels, and both arms showed similar distribution of change in HbA1c from baseline to primary endpoint at Week 48. These results suggest that subjects in the tarcocimab arm achieved superiority in ≥2-step improvement in DRSS over sham injections irrespective of baseline and systemic metabolic control, as evidenced by HbA1c levels, and any potential presumed knowledge by the patient about treatment assignment due to the use of sham as a comparator did not systematically influence their glycemic control..

GLOW1研究的预先指定分析表明，通过HbA1c水平测量，塔科单抗治疗组和假手术组的全身代谢控制变化可忽略不计，并且在第48周，两组均显示HbA1c从基线到主要终点的变化分布相似。这些结果表明，无论基线和全身代谢控制如何，tarcocimab组的受试者在DRSS改善≥2步方面均优于假注射，HbA1c水平以及患者对治疗分配的任何潜在推测知识都证明了这一点。使用假手术作为比较物并没有系统地影响他们的血糖控制。。

Title: An embryo-fetal development study of tarcocimab after intravenous injection in rabbitsSession Title: Retina/RPE: New drugs, mechanisms of action, and toxicitySession Date and Time: May 8, 2024; 2:15 – 4:00 PM PTPresentation Type: Poster SessionPoster Number: 5100 – A0357

标题：兔静脉注射塔科单抗后的胚胎-胎儿发育研究会议标题：视网膜/视网膜色素上皮：新药，作用机制和毒性会议日期和时间：2024年5月8日；2： 下午15:00–4:00 PT演示类型：海报会议海报编号：5100–A0357

The non-clinical study demonstrated that maternal administration of tarcocimab to New Zealand White female rabbits by intravenous injection at the highest tested dose of 5 mg/kg during the organogenesis period of pregnancy was well tolerated. There were no tarcocimab related mortality or abortions for any dosage regimen, and no effects on embryo-fetal viability or fetal body weights, as well as no malformations or variations at external, visceral, or skeletal examination.

非临床研究表明，在怀孕的器官发生期间，通过静脉注射最高测试剂量5 mg/kg的新西兰白兔，母体对tarcocimab的耐受性良好。任何剂量方案都没有与tarcocimab相关的死亡率或流产，对胚胎-胎儿活力或胎儿体重没有影响，在外部，内脏或骨骼检查中也没有畸形或变异。

These results continue to highlight the favorable safety profile of tarcocimab and of Kodiak's ABC platform and compare favorably to published results with marketed anti-VEGF agents which have demonstrated embryo-fetal development effects in animal studies..

这些结果继续突出了tarcocimab和Kodiak的ABC平台的良好安全性，并与已在动物研究中证明胚胎-胎儿发育效应的市售抗VEGF药物的公布结果进行了比较。。

Presentations on KSI-501:

KSI-501演示：

Title: Ocular and systemic toxicity study of KSI-501 demonstrates tolerability after intravitreal and intravenous administration in cynomolgus monkeys Session Title: Retina/RPE: New drugs, mechanisms of action, and toxicitySession Date and Time: May 8, 2024; 2:15 – 4:00 PM PTPresentation Type: Poster SessionPoster Number: 5094 – A0351.

标题：KSI-501的眼部和全身毒性研究证明了食蟹猴玻璃体内和静脉内给药后的耐受性会议标题：视网膜/视网膜色素上皮：新药，作用机制和毒性会议日期和时间：2024年5月8日；2： 下午15:00–4:00 PT演示类型：海报会议海报编号：5094–A0351。

The non-clinical study demonstrated that repeated monthly bilateral intravitreal administration of up to 5.25 mg/eye/dose (maximum feasible dose) or intravenous dosing of up to 5 mg/kg/dose (maximum tested dose) of KSI-501 in cynomolgus monkeys was safe and well tolerated. Due to the mild severity of findings and the lack of impact on the health and well‑being of animals administered 5 mg/kg IV or 5.25 mg/eye IVT, these doses were considered the No Observed Adverse Effect Levels (NOAELs) for systemic and ocular administration, respectively. These results provide a clear margin of safety for repeat dosing and information for adequate safety monitoring to support further clinical investigations with KSI-501 (bioconjugate) and KSI-101 (bispecific protein) which are ongoing.

非临床研究表明，在食蟹猴中，每月重复双侧玻璃体内给药高达5.25 mg/眼/剂量（最大可行剂量）或静脉内给药高达5 mg/kg/剂量（最大测试剂量）的KSI-501是安全且耐受性良好的。由于研究结果的严重程度较轻，并且对静脉注射5 mg/kg或静脉注射5.25 mg/眼的动物的健康和福祉没有影响，因此这些剂量被认为是全身和眼部未观察到的不良反应水平（NOAEL）管理，分别。这些结果为重复给药提供了明确的安全边际，并为充分的安全性监测提供了信息，以支持正在进行的KSI-501（生物缀合物）和KSI-101（双特异性蛋白）的进一步临床研究。

These results are also consistent with non-clinical data generated with tarcocimab, another ABC Platform derived therapeutic candidate, and suggest the continued safety profile of the ABC Platform..

这些结果也与另一种ABC平台衍生的治疗候选药物tarcocimab产生的非临床数据一致，并表明ABC平台的持续安全性。。

Title: KSI-501: a bispecific fusion protein antibody inhibiting both interleukin-6 and vascular endothelial growth factor. First-in-human trial results of multiple ascending doses in patients with diabetic macular edemaSession Title: Diabetic macular edemaSession Date and Time: May 9, 2024; 11:45 AM – 1:30 PM PTPresentation Type: Poster SessionPoster Number: 530 – B0162.

标题：KSI-501：一种抑制白细胞介素-6和血管内皮生长因子的双特异性融合蛋白抗体。糖尿病黄斑水肿患者多次递增剂量的首次人体试验结果标题：糖尿病黄斑水肿日期和时间：2024年5月9日；11： 上午45:00–下午1:30 PT演示类型：海报会议海报编号：530–B0162。

This first-in-human study was Part 1 of a Phase 1 multiple ascending dose study of KSI-501 in both treatment naïve and treatment experienced patients with DME. Part 1 demonstrated that repeated monthly dosing of KSI-501 was safe and well tolerated and achieved meaningful and sustained improvement in BCVA and OCT CST.

这项首次人体研究是KSI-501在未接受过治疗和接受过治疗的DME患者中进行的第一阶段多剂量递增研究的第一部分。第1部分证明，每月重复给药KSI-501是安全且耐受性良好的，并且在BCVA和OCT CST中实现了有意义的持续改善。

These results support further clinical development of both (1) KSI-501, a bispecific antibody biopolymer conjugate, for high prevalence retinal diseases to address the leading unmet needs of durability and targeting multiple disease biologies; and (2) KSI-101, a bispecific protein with high potency and high formulation strength for inflammatory diseases of the eye..

这些结果支持（1）KSI-501（一种双特异性抗体-生物聚合物缀合物）的进一步临床开发，用于高患病率视网膜疾病，以解决耐久性和针对多种疾病生物学的主要未满足需求；（2）KSI-101，一种双特异性蛋白质，对眼部炎症性疾病具有高效力和高配方强度。。

Presentations on Research Pipeline:

关于研究管道的介绍：

Title: Identification and characterization of novel NLRP3 inflammasome Inhibitors for the potential treatment of retinal disease Session Title: Treatment strategies for inherited retinal diseasePresentation Date and Time: May 6, 2024; 3:00 – 4:45 PM PTPresentation Type: Poster SessionPoster Number: 2208 – A0062.

标题：用于视网膜疾病潜在治疗的新型NLRP3炎性体抑制剂的鉴定和表征会议标题：遗传性视网膜疾病的治疗策略介绍日期和时间：2024年5月6日；3： 下午00:00–4:45 PT演示类型：海报会议海报编号：2208–A0062。

We disclose for the first time the discovery and characterization of novel NLRP3 pathway inhibitors that are potent and act on all levels of the NLRP3 pathway without non-specific anti-inflammatory action. This work highlights Kodiak's small molecule discovery capabilities, which play an important part in our development of duet and triplet therapeutic candidates designed to provide targeted high drug-antibody-ratio (DAR) and sustained therapeutic benefit for both ophthalmic and systemic diseases..

我们首次公开了新型NLRP3途径抑制剂的发现和表征，这些抑制剂有效并作用于NLRP3途径的所有水平，而没有非特异性抗炎作用。这项工作突出了Kodiak的小分子发现能力，这在我们开发二联体和三联体治疗候选药物中起着重要作用，旨在为眼科和全身性疾病提供靶向的高药物抗体比（DAR）和持续的治疗益处。。

Title: Development of anti-inflammatory bispecific trap-antibodies Session Title: Diabetic retinopathy, anti-inflammatory agents, antibiotics and antiviralsSession Date and Time: May 8, 2024; 10:30 AM - 12:15 PM PTPresentation Type: Poster SessionPoster Number: 4599 – A0328

标题：抗炎双特异性trap抗体的开发会议标题：糖尿病视网膜病变，抗炎药，抗生素和抗病毒会议日期和时间：2024年5月8日；10： 上午30:00-下午12:15 PT演示类型：海报会议海报编号：4599–A0328

We present a portfolio of novel bispecific anti-inflammatory biologics targeting proinflammatory cytokines. This work highlights the expansion of our modular trap-antibody platform and presents a group of promising therapeutic candidates with the potential to mitigate the complex effects of ocular inflammation in a controlled, multi-specific manner..

我们提出了一系列针对促炎细胞因子的新型双特异性抗炎生物制剂。这项工作突出了我们模块化trap抗体平台的扩展，并提出了一组有前途的候选治疗药物，有可能以受控的多特异性方式减轻眼部炎症的复杂影响。。

Title: Internalization of antibody biopolymer conjugate via receptor-mediated mechanismSession Title: AMD New drugs, delivery systems and mechanisms of action IISession Date/Times: May 9, 2024; 8:00 - 9:45 AM PTPresentation Type: Poster SessionPoster Number: 6120 – B1019

标题：通过受体介导的机制内化抗体-生物聚合物缀合物会议标题：AMD新药，递送系统和作用机制II会议日期/时间：2024年5月9日；8： 00-9:45 AM PT演示类型：海报会议海报编号：6120–B1019

We demonstrate that antibody biopolymer conjugates built on our ABC platform can be internalized upon binding to cell-surface receptors, a key step enabling the use of our ABC platform for cell-specific drug deliveries. The ABC platform, combined with diverse drug modalities such as oligonucleotides, small molecules and peptides including macrocycles, can overcome current limits on drug-antibody-ratio (DAR) and provide a broad range of options for multi-specific bioactive loading and targeted delivery..

我们证明，建立在我们的ABC平台上的抗体-生物聚合物缀合物可以在与细胞表面受体结合后内化，这是使用我们的ABC平台进行细胞特异性药物递送的关键步骤。ABC平台与寡核苷酸，小分子和肽（包括大环化合物）等多种药物形式相结合，可以克服目前药物抗体比（DAR）的限制，并为多特异性生物活性负载和靶向递送提供广泛的选择。。

Title: Development of enhanced complement regulators for the treatment of geographic atrophySession Title: AMD New drugs, delivery systems and mechanisms of action IISession Date/Times: May 9, 2024; 8:00 – 9:45 AM PTPresentation Type: Poster SessionPosterboard Number: 6119 – B1018

标题：开发用于治疗地理萎缩的增强补体调节剂会议标题：AMD新药，递送系统和作用机制II会议日期/时间：2024年5月9日；8： 00–9:45 AM PT演示类型：海报会话Postboard编号：6119–B1018

Geographic atrophy (GA), the advanced form of dry age-related macular degeneration, affects approximately one million patients in the U.S. and is characterized by atrophic lesions in the retina that progressively expand to the central macular and fovea, leading to irreversible vision loss. Currently there are two approved therapies for GA, both are anti-complement therapies that offer modest therapeutic benefit and require monthly or every other month intravitreal injections.

地理萎缩（GA）是干性年龄相关性黄斑变性的高级形式，在美国约有100万患者受到影响，其特征是视网膜萎缩性病变逐渐扩展至中央黄斑和中央凹，导致不可逆转的视力丧失。目前有两种经批准的GA疗法，都是抗补体疗法，可提供适度的治疗益处，需要每月或每隔一个月进行玻璃体内注射。

Here we present a promising therapeutic strategy to treat GA and potentially wet AMD by combining complement regulators with an anti-VEGF Fab to achieve potent, concurrent inhibition of complement pathway activation and VEGF pathway signaling..

在这里，我们提出了一种有前途的治疗策略，通过将补体调节剂与抗VEGF Fab相结合来治疗GA和潜在的湿性AMD，以实现对补体途径激活和VEGF途径信号传导的有效，同时抑制。。

About Kodiak Sciences Inc.

关于Kodiak Sciences Inc。

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally.

Kodiak Sciences（纳斯达克股票代码：KOD）是一家生物制药公司，致力于研究，开发和商业化转化疗法，以治疗广泛的视网膜疾病。我们致力于为下一代视网膜药物的设计和制造带来新的科学，以预防和治疗全球失明的主要原因。

Our ABC Platform™ uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three clinical programs, two of which are late-stage today and derived from our ABC Platform and one which is platform-independent and which we believe can progress rapidly into pivotal studies..

我们的ABC Platform™利用分子工程将基于蛋白质和基于化学的疗法领域融合在一起，一直是Kodiak发现引擎的核心。我们正在开发一个由三个临床项目组成的投资组合，其中两个是目前处于后期阶段的，来自我们的ABC平台，另一个是独立于平台的，我们相信可以迅速进入关键研究。。

Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases including diabetic retinopathy, the leading cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world..

Kodiak的主要研究药物tarcocimab是一种新型的抗VEGF抗体生物聚合物偶联物，正在开发中，用于治疗高发病率的视网膜血管疾病，包括糖尿病视网膜病变（发达国家工龄患者失明的主要原因）和湿性年龄相关性黄斑变性（发达国家老年患者失明的主要原因）。。

KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of targeting multiple biologies and extended durability..

KSI-501是我们的第二种研究药物，是一流的抗IL-6，VEGF陷阱双特异性抗体生物聚合物偶联物，旨在抑制IL-6介导的炎症和VEGF介导的血管生成和血管通透性。KSI-501正在开发用于治疗高患病率视网膜血管疾病，以解决针对多种生物学和延长耐久性的未满足需求。。

Additionally, Kodiak is developing a third product candidate, KSI-101, a novel anti-IL-6, VEGF-trap bispecific protein, the unconjugated protein portion of KSI-501. Kodiak intends to develop KSI-101 for the treatment of retinal inflammatory diseases, as currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina..

此外，Kodiak正在开发第三种候选产品KSI-101，一种新型抗IL-6，VEGF陷阱双特异性蛋白，KSI-501的未结合蛋白部分。Kodiak打算开发用于治疗视网膜炎性疾病的KSI-101，因为目前还没有可用的玻璃体内生物疗法来解决视网膜炎症的范围。。

Kodiak has expanded its early research pipeline of duet and triplet inhibitors that embed small molecules and other bioactive molecules in the biopolymer backbone to provide a high drug-antibody ratio ('DAR'). The diverse active pharmaceutical intermediates (API) are designed to be released over time to achieve sustained modulation of targeted biological pathways.

Kodiak已经扩大了其早期的二联体和三联体抑制剂的研究渠道，这些抑制剂将小分子和其他生物活性分子嵌入生物聚合物骨架中，以提供高药物抗体比（“DAR”）。各种活性药物中间体（API）被设计为随着时间的推移而释放，以实现对靶向生物途径的持续调节。

The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial ophthalmic and systemic diseases..

高DAR和定制治疗益处的独特组合为多因素眼科和全身性疾病的广泛应用提供了潜力。。

For more information, please visit www.kodiak.com.

有关更多信息，请访问www.kodiak.com。

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Kodiak®、Kodiak Sciences®、ABC™、ABC Platform™和Kodiak徽标是Kodiak Sciences Inc.在全球各个司法管辖区的注册商标或商标。

Forward-Looking Statements

前瞻性声明

This release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: the continued favorable safety profile of tarcocimab; next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101; the potential for targeted, high drug-antibody-ratio conjugates built on Kodiak's ABC Platform; the potential for the duet and triplet drug platform; promising therapeutic candidates with the potential to mitigate the complex effects of ocular inflammation; and a promising therapeutic strategy to treat GA and potentially wet AMD by combining complement regulators with an anti-VEGF Fab to achieve potent, concurrent inhibition of complement pathway activation and VEGF pathway signaling.

本新闻稿包含《1933年证券法》第27A节、《1934年证券交易法》第21E节和《1995年私人证券诉讼改革法》所指的“前瞻性声明”。这些前瞻性声明不是基于历史事实，包括关于以下方面的声明：塔科昔单抗持续良好的安全性；KSI-501第3阶段开发和KSI-101第1b阶段开发的后续步骤；建立在Kodiak的ABC平台上的靶向，高药物-抗体比率缀合物的潜力；二重奏和三重奏药物平台的潜力；有希望的治疗候选人，有可能减轻眼部炎症的复杂影响；以及通过将补体调节剂与抗VEGF Fab结合来治疗GA和潜在湿性AMD的有希望的治疗策略，以实现对补体途径激活和VEGF途径信号传导的有效，同时抑制。

Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'could,' 'expect,' 'plan,' 'believe,' 'intend,' 'pursue,' and other similar expressions among others.

前瞻性陈述通常包括具有预测性的陈述，取决于或涉及未来的事件或条件，并包括诸如“可能”、“将会”、“应该”、“将会”、“可能”、“期望”、“计划”、“相信”、“打算”、“追求”等类似的表达。

Any forward-looking statements are based on management's current expectations of future events and are subject to a risks and uncertainties that could cause actual results to differ materially and adversely from those in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: cessation or delay of any clinical studies and/or development of KSI-501 may occur; the risk that KSI-501 may not inhibit VEGF and IL-6, provide extended durability or have an impact on the treatment of patients.

任何前瞻性声明都是基于管理层目前对未来事件的预期，并受到可能导致实际结果与此类前瞻性声明中或暗示的结果产生重大不利差异的风险和不确定性的影响。这些风险和不确定性包括但不限于：可能停止或延迟任何临床研究和/或开发KSI-501；KSI-501可能不抑制VEGF和IL-6，延长耐久性或对患者治疗产生影响的风险。

SOURCE Kodiak Sciences Inc.

来源：Kodiak Sciences Inc。